Dr Reddy's receives EIR from USFDA for API manufacturing; stock up 1%

The pharma company has received an establishment inspection report from the US health regulator for its Nalgonda-based active pharmaceutical ingredient manufacturing unit.

from India Infoline News Service https://ift.tt/3c5CBGW